Latest Articles

PCSK9i and Prevention of CVD

The synopsis of a Cochrane Systematic review on PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.

PCSK9 Inhibitors in Real World Practice

PCSK9i after hospital discharge for acute MI

Factors associated with time to PCSK9i initiation following hospital discharge for acute myocardial infarction.

LDL-C Targets in Patients with Heterozygous Familial Hypercholesterolemia

LDL-C The Only Causal Risk Factor for ASCVD

Meta Analysis of apoB Lowering and CV Risk Reduction Among Different LLTs

Galimberti F, et al. Poster presented at the 91st European Atherosclerosis Society congress (EAS) 2023.

Management of Patients With Very High Cardiovascular Risk Eligible for PCSK9 Inhibitor Treatment: 1-year Outcomes of The PERI-DYS Study

Lipid-lowering therapy and care gap in patients with Familial Hypercholesterolemia

Lp(a) as ASCVD risk factor